Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020113050 - FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENT

Publication Number WO/2020/113050
Publication Date 04.06.2020
International Application No. PCT/US2019/063671
International Filing Date 27.11.2019
IPC
A61K 31/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
14Quaternary ammonium compounds, e.g. edrophonium, choline
A61K 31/397 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
397having four-membered rings, e.g. azetidine
A61K 47/10 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen
10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols ; Poloxamers; PEG/POE alkyl ethers
CPC
A61K 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
14Quaternary ammonium compounds, e.g. edrophonium, choline
A61K 31/397
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
397having four-membered rings, e.g. azetidine
A61K 47/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen, ; e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Applicants
  • ASANA BIOSCIENCES, LLC [US]/[US]
Inventors
  • AUDETT, Jay
  • GOSWANI, Tarun
  • SUCHDEVA, Sameer
  • BANSAL, Padam
  • RAO, Niranjan
  • JIMENEZ, Pablo
Agents
  • BARTOW, William L.
Priority Data
62/773,27730.11.2018US
62/840,72630.04.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENT
(FR) FORMULATIONS, MÉTHODES, KIT ET FORMES POSOLOGIQUES PERMETTANT UNE STABILITÉ AMÉLIORÉE D'UN PRINCIPE ACTIF PHARMACEUTIQUE
Abstract
(EN)
Embodiments of the disclosure relate generally to formulations, methods, kits, and dosage forms for improved topical pharmaceutical formulation comprising an active ingredient, wherein the active ingredient comprises a compound selected from the group consisting of the Formula (I), Formula (II), and Formula (III): The formulations can further comprise a hydrophilic non-ionic surfactant comprising a poloxamer. These formulations are useful in treating inflammation, pruritus and/or pain, or for treating conditions for which the signs and symptoms include inflammation, pruritis and/or pain, by topical administration to a subject.
(FR)
L'invention, selon certains modes de réalisation, concerne de manière générale des formulations, des méthodes, des kits et des formes posologiques de formulation pharmaceutique topique améliorée comprenant un principe actif, le principe actif comprenant un composé choisi dans le groupe constitué par la formule (I), la formule (II) et la formule (III). Les formulations peuvent en outre comprendre un tensioactif non ionique hydrophile comprenant un poloxamère. Ces formulations sont utiles dans le traitement d'une inflammation, d'un prurit et/ou d'une douleur, ou pour le traitement de problèmes de santé pour lesquels les signes et les symptômes comprennent une inflammation, un prurit et/ou une douleur, par administration topique à un sujet.
Latest bibliographic data on file with the International Bureau